

A MONTHLY SIP OF **₹10,000**
 WOULD HAVE BECOME
~₹27.79 LACS WHILE THE
 BENCHMARK WOULD
 HAVE BECOME **₹22.58 LACS**



Essential for your
 portfolio's health

First Installment date 01-Jan-16

TATA

INDIA PHARMA & HEALTHCARE FUND

(An open-ended equity scheme investing in Pharma & Healthcare Services Sector)

Data as on 30th June 2025

For detailed performance, refer to the table below.

SIP PERFORMANCE

SIP RETURNS		Tata India Pharma And Healthcare Fund		Nifty Pharma TRI		Nifty 50 TRI	
Period	Amt. invested	Returns	Rs.	Returns	Rs.	Returns	Rs.
1 Year	1,20,000	5.55%	1,23,528	3.39%	1,22,160	12.43%	1,27,829
3 Year	3,60,000	23.98%	5,09,638	22.27%	4,97,841	16.12%	4,56,731
5 Year	6,00,000	19.74%	9,80,093	17.34%	9,24,436	16.08%	8,96,353
Since Inception	11,40,000	17.94%	27,78,763	13.84%	22,57,723	15.32%	24,33,201

First Installment date 01-Jan-16

Fund Manager: Meeta Shetty (Managing Since 09-Nov-18) & Rajat Srivastava (Managing Since 16-Sep-24)

Monthly investment of Rs 10,000 invested on the 1st day of every month has been considered. Past performance may or may not be sustained in future.

SCHEME PERFORMANCE IN SEBI FORMAT

Returns	Tata India Pharma And Healthcare Fund		Nifty Pharma TRI		Nifty 50 TRI	
Period	Returns	Rs.	Returns	Rs.	Returns	Rs.
1 Year	15.08%	11,517	12.48%	11,255	7.49%	10,754
3 Year	25.14%	19,607	22.86%	18,554	18.72%	16,741
5 Year	21.99%	27,032	17.99%	22,875	21.33%	26,307
Since Inception	12.32%	30,197	7.31%	19,566	14.49%	36,234

Inception Date 28-Dec-15

Investment Amount - Rs 10,000

Performance of other funds managed by the Fund Managers

MEETA SHETTY	Lumpsum (in %)			SIP (in %)		
	1 Year	3 Year	5 Year	1 Year	3 Year	5 Year
Tata Focused Fund	1.06	19.89	22.72	2.64	15.55	16.60
Nifty 500 TRI	5.64	21.97	24.02	11.61	18.94	18.69
Tata Large & Mid Cap Fund	2.86	20.85	22.82	7.45	16.03	17.40
Nifty Large Midcap 250 TRI	6.00	24.96	26.88	12.59	21.29	21.20
Tata Digital India Fund	8.27	17.29	28.04	-0.60	16.17	16.38
Nifty IT TRI	9.90	14.19	23.84	-1.35	12.99	12.73
Tata Multicap Fund	-0.55	NA	NA	5.35	NA	NA
NIFTY 500 Multicap 50:25:25 TRI	5.73	NA	NA	12.39	NA	NA
Tata India Innovation Fund	NA	NA	NA	NA	NA	NA
Nifty 500 TRI	NA	NA	NA	NA	NA	NA

Disclaimer: 1) Scheme returns in terms of CAGR are provided for past 1 year, 3 years, 5 years and since inception. 2) Point-to-point returns on a standard investment of Rs. 10,000/- are in addition to CAGR for the schemes. 3) Different plans shall have a different expense structure. The performance details provided herein are of regular plan growth option 4) NA stands for schemes in existence for more than 1 year but less than 3 years or 5 years, or instances where benchmark data for corresponding period not available. 5) Period for which schemes performance has been provided is computed basis last day of the month - ended preceding the date of advertisement. 6) For computation of since inception returns the allotment NAV has been taken as Rs. 10.00 Schemes in existence for less than 6 months, performance details for the same are not provided. 7) Scheme in existence for more than six months but less than one year, simple annualized growth rate of the scheme for the past 6 months from the last day of month-end is provided. 8) For Benchmark Indices Calculations, Total Return Index (TRI) has been used. Where ever TRI not available Composite CAGR has been disclosed. Please refer Disclaimer sheet for composite CAGR disclosure. 9) Total Schemes managed by Meeta Shetty: 6 & Rajat Srivastava: 1.


TATA
INDIA PHARMA & HEALTHCARE FUND
 (An open-ended equity scheme investing in Pharma & Healthcare Services Sector)

This product is suitable for investors who are seeking*:


- Long Term Capital Appreciation.
- Investment in equity/equity related instruments of the companies in Information Technology Sector.

*** Investors should consult their financial advisors if in doubt about whether the product is suitable for them.**

Scheme Riskometer



Benchmark Riskometer



It may be noted that risk-o-meter specified above is based on internal assessment. The same shall be updated as per provision no. 17.4.1.i of SEBI Master Circular on Mutual Fund dated 27.06.2024, on Product labelling in mutual fund schemes on ongoing basis.